| |
|
|
|
|
|
|
|||
|
Blood, 15 January 2009, Vol. 113, No. 3, pp. 575-584. Prepublished online as a Blood First Edition Paper on October 7, 2008; DOI 10.1182/blood-2008-04-151803.
Submitted April 16, 2008
Laboratory of Immunology, Intramural Research Program, National Institute of Aging, National Institute of Health, Baltimore, MD, United States * Corresponding author; email: taubd{at}grc.nia.nih.gov.
Dexamethasone (DM) is a synthetic member of the glucocorticoid (GC) class of hormones that possesses anti-inflammatory and immunosuppressant activity and is commonly utilized to treat chronic inflammatory disorders, severe allergies and other disease states. While GC are known to mediate well-defined transcriptional effects via GC receptors (GCR), there is increasing evidence that GC also initiate rapid non-genomic signaling events in a variety of cell types. Here, we report that DM induces the phosphorylation of Lck and the activation of other down stream mediators including p59Fyn, Zap70, Rac1 and Vav in resting but not activated human T cells. DM treatment also augments CXCL12-mediated signaling in resting T cells through its cell surface receptor, CXCR4 resulting in the enhanced actin polymerization, Rac activation and cell migration upon ligand exposure. Lck was found to be a critical intermediate in these DM-induced signaling activities. Moreover, DM-mediated Lck phosphorylation in T cells was dependent on the presence of both the GCR and the CD45 molecule. Overall, these results elucidate additional non-genomic effects of DM and the GCR on resting human T cells, inducing Lck and downstream kinase activation and augmenting chemokine signaling and function.
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2008 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||